Categories AlphaGraphs, Earnings, Other Industries
Earnings preview: Teva’s struggles might not end in Q2
Teva Pharmaceuticals (NYSE: TEVA) is scheduled to report second quarter 2019 earnings results on Wednesday, August 7, before market open. Analysts expect to report earnings of $0.57 per share on revenue of $4.25 billion.
Teva has been struggling with tough competition and pricing challenges in the generics market and this is expected to continue in the second quarter. Revenue declines in Copaxone as well as other key brands is also expected to hurt the top line numbers. Teva is also likely to see pressure in Europe due to discontinued business operations.
However, the company is expected to benefit from the sales of new products which are likely to partially offset the weakness in other areas. Cost-saving efforts are expected to help margins during the quarter. Updates on the company’s new product launches and approvals for new indications are areas to keep an eye out for.
In the first quarter of 2019, Teva beat earnings estimates but revenues missed expectations. Revenues fell 15% to $4.3 billion while adjusted EPS dropped 36% to $0.60. Revenues decreased in all geographic regions. Generic products and Copaxone saw sales declines across all markets.
For the full year of 2019, Teva has guided for revenues in the range of $17-17.4 billion and adjusted EPS in the range of $2.20-2.50.
Teva’s shares have dropped 50% year-to-date and 17% over the past one month. The majority of analysts have rated the stock Hold and it has a price target of $10.75.
Most Popular
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Target (TGT): A look at some of the challenges faced by the retailer in 3Q24
Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and